Letter of Intent (the “ LOI ” ) with S-Ray INCORPORATED
FORM 8-K
(Current report filing)
Filed 10/21/14 for the Period Ending 10/21/14
Address
Telephone CIK Symbol SIC Code Industry Sector Fiscal Year
17475 GILLETTE AVENUE IRVINE, CA 92614
(949) 273-4990 0001329606
CETY
3672 – Printed Circuit Boards Electronic Instr. & Controls Technology
12/31
http://www.edgar-online.com
© Copyright 2014, EDGAR Online, Inc. All Rights Reserved.
Distribution and use of this document restricted under EDGAR Online, Inc. Terms of Use.
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): October 20, 2014 PROBE MANUFACTURING, INC.
(Exact name of Company as specified in its charter)
333-125678
(Commission File Number)
17475 Gillette Blvd.,
Irvine, CA 92614
(Address of principal executive offices)
Phone: (949) 273-4990
(Company ’ s Telephone Number)
Nevada
(State or other jurisdiction of Incorporation)
20-2675800
(IRS Employer Identification Number)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 8.01 Other Events
On or about October 21, 2014, Probe Manufacturing, Inc., a public Nevada corporation (the “ Company ” ), located at 17475 Gillette Blvd., Irvine CA 92614, entered into a letter of intent (the “ LOI ” ) with S-Ray INCORPORATED, a private Nevada corporation ( “ S-Ray ” ), located at 50 West Liberty Street, Suite 880, Reno Nevada 89501, which provides that the Company will issue S-Ray 75,000,000 shares of restricted Company common stock in exchange for 1,000,000 shares of S-Ray restricted common stock (the “ Share Exchange Agreement ” ). The 1,000,000 shares of S-Ray will be distributed to the Company ’ s shareholders of record as of
October 31, 2014, on a pro-rata basis. In conjunction with the LOI, S-Ray has also agreed to work with the existing note holders, including the potential extinguishment of the existing notes, at the closing of the Share Exchange Agreement. Further, the LOI outlines that in the potential Share Exchange Agreement, S-Ray would commit to signing a manufacturing and distribution rights agreement with the Company for its ClearScan LAB product wherein the terms of the distribution rights agreement would be similar to the following:
a. The Company would book the revenue from the product sales; regardless, if it was to a single customer such as a distributor or to individual clients;
b. The Company would maintain control of manufacturing costs and profits;
c. S-Ray would be paid an annual royalty of 6% of total ClearView LAB revenue;
d. The distribution rights agreement would be for a minimum of 3 years and a maximum of 5 years; and,
e. The Company would have the right to sell or assign the distribution rights agreement to another suitable
manufacturing partner.
S-Ray further believes that it will be able to assist the Company in raising capital, and the purchasing of
equipment in order to prepare for the manufacturing, testing and fulfillment of the ClearView LAB product. S-Ray will also assist the Company in establishing commercial banking services including credit lines and debt.
The Company and S-Ray agree to make their best efforts to close and finalize the proposed Share Exchange Agreement within 60 days of the signing of the LOI. The Share Exchange Agreement is subject to shareholder approval by the Company ’ s shareholders, and a due diligence period of up to 60 days with the closing proposed on or before December 20, 2014. This transaction is also subject to a due diligence investigation of the operations of S- Ray by the Company.
The foregoing summary description of the terms of the Letter of Intent may not contain all information that is of interest to the reader. For further information regarding the terms and conditions of the Letter of Intent, this reference is made to such agreement, which is filed as Exhibit 10.1 hereto and is incorporated herein by this reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
Exhibits (d)
Exhibit No. Description of Exhibit
10.1
Letter of Intent between the Company and S-Ray INCORPORATED, dated October 20, 2014
SIGNA TURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Probe Manufacturing, Inc.
Date: October 21, 2014 By: /s/ Kambiz Mahdi Kambiz Mahdi
Chief Executive Officer

October 14, 2014
Kam Mahdi
Chief Executive Officer
Probe Manufacturing, Incorporated
RE: Letter of Intent Dear Kam:
Please allow this Letter of Intent to memorialize our discussions regarding a strategic, long term partnership between Probe and S-Ray.
1. All Probe shareholders of record as of October 31, 2014 will be issued shares from a pool of 1,000,000 shares of S-Ray common stock on a pro rata basis in exchange for 75,000,000 shares of Probe common stock.
2. With respect to existing Probe shareholders holding preferred convertible positions, I am prepared to accommodate their goals, including payment of existing notes, at closing.
3. I would be honored to be invited to join the Probe board of directors and would accept the
position of Chairman if offered.
4. This transaction is conditioned upon approval of a majority of Probe shareholders.
5. Both parties agree to make best efforts to close this proposed transaction within 60 days or
sooner.
6. S-Ray is prepared to sign a manufacturing and distribution rights agreement with Probe for our
ClearScan LAB product.
a. Probe would book the revenue from the product sales, regardless if it was to dental
laboratories or individual dentists.
b. The agreement would allow Probe to control manufacturing costs and profits.
c. S-Ray would be paid an annual royalty of 6% of total ClearView LAB revenue.
d. The agreement would be a minimum of 3 years and a maximum of 5 years in term.
e. Probe would have the right to sell or assign the agreement to another suitable
manufacturing partner.
7. S-Ray is currently accepting investment for ultrasound product development, including
manufacturing equipment. S-Ray believes it would be efficient to assist Probe with both capital and equipment to prepare for the manufacturing, testing and fulfillment of the ClearView LAB product.
8. I would make personal efforts to assist in the capitalization of Probe using my relationships with the 150 S-Ray investors as well as our new investors.
9. I am prepared to assist Probe in establishing commercial banking services including credit lines and debt, as needed, using my personal relationships and assets, including a personal guarantee if required.
50 West Liberty Street Suite 880 Reno Nevada 89501 USA
In closing, if your board of directors agrees with the points of this Letter of Intent, I am prepared to move forward immediately and close this transaction in a matter of weeks. I look forward to our next conversation, Kam.
Sincerely,
/s/ Steve Baird
Steve Baird
Chief Executive Officer
Acceptance:
/s/ Kam Mahdi ________ Kam Mahdi, CEO
Probe Manufacturing, Inc.
10/20/14 _______ Date
Page 2 of 2